Lilly Research Laboratories's galcanezumab moved into the lead in the treatment of cluster headaches with a calcitonin gene-related peptide (CGRP) inhibitor via Phase III data reported May 15, but analysts wonder how much of an impact this will have in the ultra-competitive CGRP space.
The Indianapolis pharma said that galcanezumab hit the primary endpoint in a 106-patient, Phase III study in episodic cluster headaches,...
Welcome to Scrip
Create an account to read this article
Already a subscriber?